Whole-body Hyperthermia for Depression

Randomised Sham-controlled Trial of Whole-body Hyperthermia for Depression

The goal of this clinical trial is to test the efficacy of whole-body hyperthermia in major depression. The main question it aims to answer is:

• Does whole-body hyperthermia alleviate symptoms of depression?

Participants will be randomised to sham or active whole-body hyperthermia. The study will last 6 weeks during which five visits will take place. Depression will be measured repeatedly and biological mechanisms will be investigated.

Study Overview

• Status: Recruiting
• Conditions: Major Depressive Disorder
• Intervention / Treatment: Device: Active whole-body hyperthermia; Device: Sham whole-body hyperthermia

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Susanne Fischer, PhD; Phone Number: +41446357460; Email: s.fischer@psychologie.uzh.ch

Study Locations

• Switzerland
  • Zurich, Switzerland, 8050
    • Recruiting
    • University of Zurich, Institute of Psychology
    • Contact: Susanne Fischer, PhD; Phone Number: +41446357460; Email: s.fischer@psychologie.uzh.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• mental capacity to make decisions
• informed consent signed by the subject
• fluent in the German language
• 18-65 years of age
• pre-menopausal women: willing to use birth control or not to engage in sexual intercourse for the duration of the study (the latter only in the case that this corresponds to the habitual lifestyle of this person)
• fulfil DSM-5 criteria for a major depressive episode
• score ≥ 14 on the Hamilton Rating Scale for Depression (HAMD-17; minimum: 0, maximum: 68, higher scores indicate higher depression)
• the major depression is the primary mental disorder

Exclusion Criteria:

• vulnerable subjects
• known or suspected non-compliance, drug or alcohol abuse within the past 2 years
• inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject
• participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation
• previous enrolment into the current investigation
• enrolment of the Sponsor-Investigator, her family members, employees and other dependent persons
• contraindications and limitations of the MD as described in the instructions for use
• BMI > 30
• lifetime schizophrenia, lifetime bipolar disorder, current catatonic or psychotic symptoms, current suicidal ideation, current severe claustrophobia, anorexia or bulimia nervosa within the past 5 years
• metallic, silicone, or saline implants
• cardiovascular conditions or problems, including uncontrolled hypertension, congestive heart failure, or documented evidence of coronary artery disease
• chronic conditions/diseases associated with a reduced ability to initiate thermoregulatory cooling, including Parkinson's, multiple sclerosis, central nervous system tumors, and diabetes with neuropathy
• history of peripheral circulatory disease, including peripheral vascular disease and deep vein thrombosis
• history of a cerebral vascular accident
• history of epilepsy or cerebral aneurisms
• cancer in the last five years, except for resected non-melanoma skin cancer
• any clinically significant autoimmune disease
• hemophilia or proneness to bleeding
• fever the day of study intervention
• hypersensitivity to heat
• recent acute joint injury
• enclosed infections, be they dental, in joints, or in any other tissues
• any other medical condition or disorder that is unstable and clinically significant, or that could interfere with the accurate assessment of safety or efficacy of treatment
• intake of medication interfering with thermoregulatory cooling, including barbiturates, diuretics, beta-blockers, and anti-histamines
• intake of psychotropic medication within 2 weeks (8 weeks for fluoxetine)
• need for psychotropic medication during the study period
• current psychotherapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Active whole-body hyperthermia	Device: Active whole-body hyperthermia; Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
Sham Comparator: Sham whole-body hyperthermia	Device: Sham whole-body hyperthermia; Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hamilton Rating Scale for Depression (HAMD-17; minimum: 0, maximum: 68, higher scores indicate higher depression)	Depressive symptoms (observer-rated)	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Beck Depression Inventory (BDI; minimum: 0, maximum: 63; higher scores indicate higher depression)	Depressive symptoms (self-reported)	1 week and 6 weeks
Medical Outcomes Study 36-item short-form health survey (MOS-SF; minimum: 0, maximum: 100, higher scores indicate better health status)	Quality of life	1 week and 6 weeks
Hamilton Rating Scale for Depression (HAMD-17; minimum: 0, maximum: 68, higher scores indicate higher depression)	Depressive symptoms (observer-rated)	6 weeks

Collaborators and Investigators

• Sponsor: University of Zurich
• Investigators: Principal Investigator: Susanne Fischer, PhD, University of Zurich

Study record dates

Study Major Dates

• Study Start (Estimated): June 15, 2024
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: February 28, 2024
• First Submitted That Met QC Criteria: March 14, 2024
• First Posted (Actual): March 21, 2024

Study Record Updates

• Last Update Posted (Actual): June 11, 2024
• Last Update Submitted That Met QC Criteria: June 10, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Mood Disorders; Wounds and Injuries; Body Temperature Changes; Heat Stress Disorders; Depressive Disorder; Depressive Disorder, Major; Hyperthermia
• Other Study ID Numbers: 2022-D0067

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No